Literature DB >> 19945803

The endogenous opioid system: a common substrate in drug addiction.

José Manuel Trigo1, Elena Martin-García, Fernando Berrendero, Patricia Robledo, Rafael Maldonado.   

Abstract

Drug addiction is a chronic brain disorder leading to complex adaptive changes within the brain reward circuits that involve several neurotransmitters. One of the neurochemical systems that plays a pivotal role in different aspects of addiction is the endogenous opioid system (EOS). Opioid receptors and endogenous opioid peptides are largely distributed in the mesolimbic system and modulate dopaminergic activity within these reward circuits. Chronic exposure to the different prototypical drugs of abuse, including opioids, alcohol, nicotine, psychostimulants and cannabinoids has been reported to produce significant alterations within the EOS, which seem to play an important role in the development of the addictive process. In this review, we will describe the adaptive changes produced by different drugs of abuse on the EOS, and the current knowledge about the contribution of each component of this neurobiological system to their addictive properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945803     DOI: 10.1016/j.drugalcdep.2009.10.011

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  72 in total

1.  The role of endogenous dynorphin in ethanol-induced state-dependent CPP.

Authors:  Khanh Nguyen; Andy Tseng; Paul Marquez; Abdul Hamid; Kabirullah Lutfy
Journal:  Behav Brain Res       Date:  2011-10-29       Impact factor: 3.332

2.  Sex differences in the effects of adolescent social deprivation on alcohol consumption in μ-opioid receptor knockout mice.

Authors:  Yuki Moriya; Yoshiyuki Kasahara; F Scott Hall; Yasufumi Sakakibara; George R Uhl; Hiroaki Tomita; Ichiro Sora
Journal:  Psychopharmacology (Berl)       Date:  2014-11-04       Impact factor: 4.530

Review 3.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

4.  Mephedrone alters basal ganglia and limbic dynorphin systems.

Authors:  Christopher L German; Mario E Alburges; Amanda J Hoonakker; Annette E Fleckenstein; Glen R Hanson
Journal:  Synapse       Date:  2014-09-08       Impact factor: 2.562

Review 5.  Neurochemical and neurostructural plasticity in alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  ACS Chem Neurosci       Date:  2012-04-16       Impact factor: 4.418

Review 6.  Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit.

Authors:  Adeleke D Adewumi; Christine E Staatz; Samantha A Hollingworth; Jason P Connor; Rosa Alati
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

7.  Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse.

Authors:  Sarah Sushchyk; Zheng-Xiong Xi; Jia Bei Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-02-22       Impact factor: 4.030

Review 8.  A review of pharmacogenetic studies of substance-related disorders.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

Review 9.  Sex differences in drug addiction and response to exercise intervention: From human to animal studies.

Authors:  Yuehui Zhou; Min Zhao; Chenglin Zhou; Rena Li
Journal:  Front Neuroendocrinol       Date:  2015-07-13       Impact factor: 8.606

10.  Alcohol dependence, disinhibited behavior and variation in the prodynorphin gene.

Authors:  Janine D Flory; Carolyn L Pytte; Yasmin Hurd; Robert E Ferrell; Stephen B Manuck
Journal:  Biol Psychol       Date:  2011-07-05       Impact factor: 3.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.